Nobivac® Lyme was specifically designed to target two key factors involved in the transmission of Lyme disease—OspA and OspC.1
Nobivac® Lyme combines 2 isolates of Borrelia burgdorferi.
- Isolate 1 is a traditional B. burgdorferi isolate that stimulates production of borreliacidal antibodies* to outer surface protein A (OspA).
- Isolate 2 is a unique isolate that stimulates the production of borreliacidal antibodies to outer surface protein C (OspC).1
Because it is made up of these 2 isolates, Nobivac® Lyme provides additional defense against B. burgdorferi infection in dogs.
The ability to target both OspA and OspC is critical to preventing transmission of B. burgdorferi from an infected tick to the dog.
OspA borreliacidal antibodies can only kill Borrelia in the feeding tick.
OspC borreliacidal antibodies can kill Borrelia in the tick and in the dog.
1. LaFleur RL, Dant JC, Wasmoen TL, et al. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. Clin Vaccine Immunol. 2009;16:253–259.